Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.
Hart AL, Ng SC. Crohn’s disease. Medicine (Baltim). 2011;39:229–36.
Doherty MM, Pang KS. First-pass effect: significance of the intestine for absorption and metabolism. Drug Chem Toxicol. 1997;20:329–44.
CAS PubMed Article Google Scholar
Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007;4:252–7.
CAS PubMed Article Google Scholar
Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190–5.
PubMed PubMed Central Article Google Scholar
Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92:1088–103.
CAS PubMed Article Google Scholar
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.
FDA. Pharmacokinetics in Patients with Impaired Hepatic Function : Study Design , Data Analysis , and Impact on Dosing and Labeling. FDA Guid [Internet]. 2003 [cited 2021 Jun 12]; Available from: https://www.fda.gov/media/71311/download.
FDA. Guidance for industry pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing. FDA Publication. 2020 [cited 2021 Jun 12]; Available from: https://www.fda.gov/media/78573/download.
Darwich AS, Henderson K, Burgin A, Ward N, Whittam J, Ammori BJ, et al. Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol. 2012;74:774–87.
CAS PubMed PubMed Central Article Google Scholar
FDA. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020 [cited 2021 Jun 20]; Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugsand/or.
Jadhav PR, Cook J, Sinha V, Zhao P, Rostami-Hodjegan A, Sahasrabudhe V, et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J Clin Pharmacol. 2015;55:1073–8.
Younis IR, Robert Powell J, Rostami-Hodjegan A, Corrigan B, Stockbridge N, Sinha V, et al. Utility of model-based approaches for informing dosing recommendations in specific populations: report from the public AAPS Workshop. J Clin Pharmacol. 2017;57:105–9.
CAS PubMed Article Google Scholar
Astrazeneca. FDA clinical pharmacology review: Entocort EC (budesonide capsules). 2009 [cited 2021 Oct 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021324s008lbl.pdf.
Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B. 1954;16:175–85.
Motulsky H. Intuitive biostatistics: a nonmathematical guide to statistical thinking. Oxford: Oxford University Press; 2010.
Olivares-Morales A, Kamiyama Y, Darwich AS, Aarons L, Rostami-Hodjegan A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur J Pharm Sci. 2015;67:32–44.
CAS PubMed Article Google Scholar
Mahid SS, Mulhall AM, Gholson RD, Eichenberger RM, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis. 2008;14:960–7.
Reddy SI, Burakoff R. Inflammatory bowel disease in African Americans. Inflamm Bowel Dis. 2003;9:380–5.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.e4.
Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42.
Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200–6.
CAS PubMed Article Google Scholar
Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjær M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274–82.
Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–8.
Moum B, Vatn MH, Ekbom A, Aadland E, Fausa O, Lygren I, et al. Incidence of Crohn’s disease in four counties in southeastern Norway, 1990–93 a prospective population-based study. Scand J Gastroenterol. 1996;31:355–61.
CAS PubMed Article Google Scholar
Jussila A, Virta LJ, Kautiainen H, Rekiaro M, Nieminen U, Färkkilä MA. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555–61.
Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian Province: a population-based study. Am J Epidemiol. 1999;149:916–24.
CAS PubMed Article Google Scholar
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
CAS PubMed Article Google Scholar
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70:439–44.
CAS PubMed Article Google Scholar
Zittan E, Kabakchiev B, Kelly OB, Milgrom R, Nguyen GC, Croitoru K, et al. Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn’s disease. J Crohns Colitis. 2016;11:jjw200.
Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14:4127.
PubMed PubMed Central Article Google Scholar
Effinger A, O’Driscoll CM, McAllister M, Fotaki N. Impact of gastrointestinal disease states on oral drug absorption—implications for formulation design—a PEARRL review. J Pharm Pharmacol. 2019;71:674–98.
CAS PubMed Article Google Scholar
McNamara PJ, Meiman D. Predicting drug binding to human serum albumin and alpha one acid glycoprotein in diseased and age patient populations. J Pharm Sci. 2019;108:2737–47.
CAS PubMed Article Google Scholar
Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metab Dispos. 2014;42:2016–22.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
PubMed PubMed Central Article Google Scholar
Certara (Simcyp). Simcyp Simulator Version 19 Help File. 2019. Certara UK Ltd., Sheffield, UK. Available from: https://members.simcyp.com/
Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225–37.
CAS PubMed PubMed Central Article Google Scholar
Wilson A, Tirona RG, Kim RB. CYP3A4 activity is markedly lower in patients with Crohnʼs disease. Inflamm Bowel Dis. 2017;23:804–13.
Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79:278–85.
CAS PubMed PubMed Central Article Google Scholar
Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.
CAS PubMed Article Google Scholar
Edsbäcker S, Bengtsson B, Larsson P, Lundin P, Nilsson Å, Ulmius J, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17:525–36.
Lundin P, Naber T, Nilsson M, Edsbacker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn’s disease. Aliment Pharmacol Ther. 2001;15:45–51.
CAS PubMed Article Google Scholar
Lundin PDP, Edsbäcker S, Bergstrand M, Ejderhamn J, Linander H, Högberg L, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol Ther. 2003;17:85–92.
CAS PubMed Article Google Scholar
Effinger A, O’Driscoll CM, McAllister M, Fotaki N. Predicting budesonide performance in healthy subjects and patients with Crohn’s disease using biorelevant in vitro dissolution testing and PBPK modeling. Eur J Pharm Sci. 2021;157:105617.
留言 (0)